This article summarizes Cingulate's registration filing, detailing its biopharmaceutical business model which uses
proprietary Precision Timed Release (PTR) technology for ADHD and anxiety medications. The company, an emerging growth
entity, reported 11,594,679 shares outstanding as of March 13, 2026, with plans to issue up to 3.5 million more, and
faces going concern risks due to losses. Proceeds from sales will fund regulatory approval, development, and
commercialization of its lead drug, CTx-1301.